Federal contract award
75F40123C00103
FY23C1EWP5 DEVELOPMENT OF NEUROBLASTOMA TISSUE DIAGNOSTIC UTILITY THROUGH FUSION OF DEEP LEARNING-BASED IMAGE ANALYTICS AND TARGETED MULTIPLEX PROTEOMICS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | B504 — Chemical/Biological Studies and Analysis |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $1.7M |
| Current contract value | $1.7M |
| Potential contract value / ceiling | $1.7M |
| Start date | Sep 20, 2023 |
| Current end date | Jan 30, 2027 |
| Potential end date | Jan 30, 2027 |
| Latest award activity | Aug 7, 2024 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 3 of 3 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 7, 2024 | P00002 | $82.8K | FY23C1EWP5 DEVELOPMENT OF NEUROBLASTOMA TISSUE DIAGNOSTIC UTILITY THROUGH FUSION OF DEEP LEARNING-BASED IMAGE ANALYTICS AND TARGETED MULTIPLEX PROTEOMICS. NO COST EXT TO ACCOMMODATE CONTRACTOR SCHEDULE DELAYS. |
| Jan 11, 2024 | P00001 | $0 | FY23C1EWP5 DEVELOPMENT OF NEUROBLASTOMA TISSUE DIAGNOSTIC UTILITY THROUGH FUSION OF DEEP LEARNING-BASED IMAGE ANALYTICS AND TARGETED MULTIPLEX PROTEOMICS. NO COST EXT TO ACCOMMODATE CONTRACTOR SCHEDULE DELAYS. |
| Sep 20, 2023 | 0 | $1.6M | FY23C1EWP5 DEVELOPMENT OF NEUROBLASTOMA TISSUE DIAGNOSTIC UTILITY THROUGH FUSION OF DEEP LEARNING-BASED IMAGE ANALYTICS AND TARGETED MULTIPLEX PROTEOMICS |
Estimated positioning window
Oct 25, 2026 – Jan 23, 2027
70/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 70/100. Available recorded signals: 65 points.
- Contract end 2027-01-30 (97 days from calculation)
- +35 points
- 15 historical awards in this buyer and category group
- +15 points
- 3 recorded award transactions
- +5 points
- Latest award action: 2024-08-07
- +0 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | May 18, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | May 18, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 17, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 17, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 9, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 9, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 9, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 9, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 4, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 4, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 4, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 4, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Jan 3, 2023 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Jan 3, 2023 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Nov 17, 2022 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Nov 17, 2022 |
| Ian Weiss | Contact | Ian.Weiss@fda.hhs.gov (301) 796-5728 | Source | Nov 14, 2022 |
| Ravi Chandan Palaniandy | Contact | RaviChandan.Palaniandy@fda.hhs.gov 301-796-4378 | Source | Nov 14, 2022 |
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.